Cancer News: Skin
An immune-system based therapy for metastatic melanoma produced lasting remissions (for more than 2 years in some cases), in a phase 1 trial.
Non-melanoma skin cancer survivors were found at higher risk for developing 30 other types of cancer later in their lives, especially those under 25 years old.
A late-stage study with an experimental vaccine was found effective, shrinking tumors in a way that indicates that it triggered the intended immune response.
European regulators have recommended the drug Mekinist (trametinib) for approval as a treatment for unresectable or metastatic melanoma in certain patients.
Lamps for drying nail polish radiate UV-A, which can cause skin cancer. However, the exposure is brief and the risk remains small, according to researchers.
New data support the potential of cobimetinib combined with vemurafenib, for the treatment of metastatic melanoma, the most aggressive form of skin cancer.
Researchers believe rapid resistance to vemurafenib (a treatment for a type of advanced melanoma) could be prevented by blocking a druggable family of proteins.
Scientists relate the difference between the responses to an experimental immunotherapy melanoma treatment primarily to the size of the tumor before treatment.
In a study, the immunotherapy drug "nivolumab" was used in advanced melanoma patients. Early results showed promise that it is likely to prolong survival.
An experimental drug, combined with an existing treatment in skin cancer patients in a clinical trial, prolonged their survival without disease progression.
A study had the controversial outcome that women who avoid sun exposure are twice as likely to die compared to those who do. Could vitamin D levels be the cause?